Peregrine shares spike on Ph2 cancer data

Shares of Peregrine Pharmaceuticals ($PPHM) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel experienced a median survival rate of 20.7 months in a prior single arm Phase II study involving 46 patients. Release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.